[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656415":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":18,"interventions":13,"overallOfficials":25,"centralContacts":29,"locations":37,"responsibleParty":54,"collaborators":58,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":13,"enrollmentInfo":73,"targetDuration":13,"studyType":76,"phases":13,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":83,"whyStopped":13,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of Zurich","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"A breath metabolite signature representing AML disease burden","A breath metabolite signature representing AML disease burden, and might represent novel AML subtypes or describe cancer metabolic status.","8 weeks",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"CASE_CONTROL","PROSPECTIVE","100 AML patients and 20 autologous-transplant controls",[19,22],{"label":20,"type":13,"description":21,"interventionNames":13},"AML","Patient with the Diagnosis (initial or relapsed\u002Frefractory) of AML",{"label":23,"type":13,"description":24,"interventionNames":13},"Negative Controls","Patients undergoing high-dose Chemotherapy with autologous stem cell support (autoHSCT) due to lymphoma or myeloma in remission",[26],{"name":27,"affiliation":5,"role":28},"Jeremy W Deuel, PD MD PhD","PRINCIPAL_INVESTIGATOR",[30,34],{"name":27,"role":31,"phone":32,"phoneExt":13,"email":33},"CONTACT","+41 41 255 11 11","haematologie-onkologie@usz.ch",{"name":35,"role":31,"phone":36,"phoneExt":13,"email":33},"Kevin D Hofer, MD","+41 255 11 11",[38],{"facility":39,"status":13,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"University Hospital of Zurich","Zurich","Canton of Zurich","8091","Switzerland","CH",{"type":46,"coordinates":47},"Point",[48,49],8.55,47.36667,{"lat":49,"lon":48},[52,53],{"name":27,"role":31,"phone":32,"phoneExt":13,"email":33},{"name":35,"role":31,"phone":32,"phoneExt":13,"email":33},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"SPONSOR_INVESTIGATOR","Jeremy Deuel","PD Dr. med. Dr. sc. nat.",[59,61],{"name":60,"class":6},"University Hospital, Zürich",{"name":62,"class":6},"ETH Zurich","100656415","real-time-breath-analysis-in-acute-myeloid-leukaemia-for-a-rapid-characterisation-of-biological-subtypes-and-to-predict-therapy-responses-100656415",false,"NCT07826897","Real-Time Breath Analysis in Acute Myeloid Leukaemia for a Rapid Characterisation of Biological Subtypes and to Predict Therapy Responses","Exhalomics for Phenotyping and Real-Time Stratification in Acute Myeloid Leukaemia (EXHALE)","EXHALE","Inclusion Criteria:\n\n* Diagnosis of an acute myeloid leukaemia and undergoing treatment\n* OR undergoing autoHSCT for lymphoid\u002Fmyeloma disease in remission\n\nExclusion Criteria:\n\n* inability to perform brath analysis\n* anatomical barriers preventing use of the mouthpiece.","ALL","18 Years",{"count":74,"type":75},120,"ESTIMATED","OBSERVATIONAL","Patients with acute myeloid leukaemia (AML) respond to treatment to differing degrees, owing to the biological diversity of the disease. The diagnostic tests currently available for identifying genetic alterations and selecting the best possible treatment usually take several days before a result is obtained. In our study, the investigators aim to determine whether breath analysis can detect metabolic products of the leukaemia that allow the disease to be classified rapidly.\n\nParticipants will undergo additional blood tests and a breath analysis during their routine appointments. This will take place only during the 1st and 2nd treatment cycles. They will also be asked to complete a questionnaire about their state of health. In addition, the study team will collect further information on their state of health (type of leukaemia, type of treatment, other medications, vital signs) from their medical records.\n\nIn total, participants will complete 4 such measurements before and during their treatment. The measurements will be coordinated with their outpatient appointments. No assessments will be carried out unless the participants are at the hospital in any case, and they will not have to attend the hospital more often because of their participation in this study.",[20],[80,81,20,82],"Exhalomics","Breath Analysis","Biomarker","NOT_YET_RECRUITING","2026-09-16",{"date":86,"type":87},"2026-09-17","ACTUAL",{"date":89,"type":75},"2026-09-21",{"date":91,"type":75},"2029-08-31",{"name":56,"class":6},1]